ID HBV Vaccination With Imiquimod in OBI

Status Completed

Clinical Trial Summary

During the course of chronic hepatitis B infection, patients may undergo hepatitis B surface antigen (HBsAg) seroclearance, resulting in undetectable circulating HBsAg. With the advance of sensitive nucleic acid detection techniques, HBsAg-negative subjects with detectable HBV DNA in sera or liver tissues can be identified. Patients who have undetectable HBsAg and yet detectable HBV DNA in sera or liver tissues are defined as having occult HBV infection (OBI). OBI as a cause of liver disease in HBsAg-negative patients remains clinically important [1,2]. Studies conducted by our research group had demonstrated that patients with HBsAg seroclearance could still develop flare of hepatitis B, advanced liver diseases and HCC [3-6]. Prevention of these complications in OBI patients by conventional intramuscular hepatitis B vaccination (HBVv) remains elusive with poor amnestic anti-HBs response [7].

The objective of this prospective double-blind randomized controlled trial is to evaluate the effect and safety of topical treatment with imiquimod immediately before intradermal vaccination with Sci-B-Vac™ in patients with OBI. Our a priori hypothesis is that imiquimod pretreatment would improve immune responses to Sci-B-Vac™ further in OBI patients, resulting in HBsAb conversion. Thereby preventing subsequent complications including flare of hepatitis, cirrhosis and HCC in these patients.

Clinical Trial Description

This randomized double-blind placebo-controlled trial will compare the safety, immunogenicity and clinical efficacy of Sci-B-Vac™ with topical ointment pretreatment among 5 groups. Group 1: Intradermal Sci-B-Vac™ with topical imiquimod ointment pretreatment; Group 2: Intradermal Sci-B-Vac™ with topical aqueous cream (placebo) pretreatment; Group 3: Intramuscular Sci-B-Vac™ with topical imiquimod ointment pretreatment.

Vaccination Regimen and Data Collection Enrolled patients will be randomized into 3 groups after written informed consent. Each patient will receive a 3 doses Sci-B-Vac™ regime at 0, 1 and 6 months. Group 1 will receive a total of 10μg intradermal HBsAg each time with topical imiquimod ointment pretreatment; Group 2 will receive a total of 10μg intradermal HBsAg each time with topical aqueous cream pretreatment. Group 3 will receive a total of 10μg intramuscular HBsAg each time with topical imiquimod ointment pretreatment.

The primary outcome measurement will be the seroprotection rate of the HBVv at 12 months after the first dose of vaccination and the secondary outcome measurements will include the seroconversion rate, the GMT fold increase and the safety of the intradermal Sci-B-Vac™ with topical imiquimod treatment at other time points. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03307902
Study type	Interventional
Source	The University of Hong Kong
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	October 1, 2016
Completion date	July 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01182311` - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed	`NCT04971928` - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment	Phase 1
Completed	`NCT03285620` - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants	Phase 1
Completed	`NCT01884415` - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis	Phase 3
Recruiting	`NCT05404919` - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates	Phase 2
Completed	`NCT02153320` - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers	Phase 1
Completed	`NCT00352963` - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).	Phase 3
Completed	`NCT03567382` - Arresting Vertical Transmission of Hepatitis B Virus	Phase 4
Not yet recruiting	`NCT04056728` - A Phase IV Study to Assess the Safety of EupentaTM Inj	Phase 4
Not yet recruiting	`NCT03604016` - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver	Phase 4
Completed	`NCT00753649` - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants	Phase 4
Recruiting	`NCT03027258` - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome	N/A
Terminated	`NCT02604199` - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection	Phase 2
Completed	`NCT02540538` - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders	Phase 1
Completed	`NCT02169674` - Hepatitis B Booster Study in Adolescence	Phase 4
Completed	`NCT02421666` - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV	N/A
Completed	`NCT01917357` - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject	Phase 3
Completed	`NCT01368497` - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection	Phase 3
Completed	`NCT01732354` - Study for Consolidation Period of Chronic Hepatitis B
Recruiting	`NCT01462981` - Cohort of Hepatitis B Research of Amsterdam	N/A